EP Patent

EP2792680A1 — Nucleoside phosphoramidate prodrugs

Assigned to Gilead Pharmasset LLC · Expires 2014-10-22 · 12y expired

What this patent protects

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing the compounds rep…

USPTO Abstract

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing the compounds represented by formula I.

Drugs covered by this patent

Patent Metadata

Patent number
EP2792680A1
Jurisdiction
EP
Classification
Expires
2014-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Pharmasset LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.